Salarius Pharmaceuticals Inc. (NASDAQ: SLRX)
$1.54
-0.2400 ( -13.50% ) 1.2M
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Market Data
Open
$1.54
Previous close
$1.78
Volume
1.2M
Market cap
$0.93M
Day range
$1.41 - $2.13
52 week range
$1.41 - $9.92
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Jul 11, 2024 |
8-k | 8K-related | 15 | Jun 17, 2024 |
8-k | 8K-related | 19 | Jun 14, 2024 |
10-q | Quarterly Reports | 45 | May 13, 2024 |
10-k/a | Quarterly Reports | 15 | Apr 22, 2024 |
4 | Insider transactions | 1 | Apr 12, 2024 |
def | Proxies and info statements | 3 | Mar 26, 2024 |
10-k | Annual reports | 55 | Mar 22, 2024 |
pre | Proxies and info statements | 4 | Mar 15, 2024 |
8-k | 8K-related | 14 | Mar 06, 2024 |